How to Build a Data-Sharing Strategy for Pharma Innovation

How to Build a Data-Sharing Strategy for Pharma Innovation

Now more than ever, the eyes of the world are on sponsors to collaborate, sharing their clinical trial data to combat human health emergencies.

While individual patient-level data sharing is largely done on a voluntary basis, privacy is just as important as when clinical studies are published by regulators.

This webinar, held in collaboration with DIA, will investigate the different decisions pharma companies face and look at how these decisions impact brand reputation and public trust.

Featured Topics:

  • Data sharing as a clinical trial sponsor’s social responsibility
  • The real-world cost of not sharing safe, insight-rich data
  • A framework for safely sharing and using sensitive clinical trial data

Learning Objectives:

  • Compare qualitative and quantitative approaches to anonymization
  • Evaluate whether to build an in-house anonymization capability, buy software, or engage a vendor
  • Analyze methods for balancing patient privacy and data utility

Presenters

Niamh McGuinness, BPharm, PHD, Senior Analyst, Clinical Trial Transparency, Privacy Analytics
Laura Dodd, Global Data Sharing Manager, PRA Health Sciences, Takeda
Jingyi Liu, Principal Research Scientist, Eli Lilly and Company

Fill in the form below to view the webinar.

Sign me up for marketing communications on safely leveraging my sensitive data.
 

About this webinar

Now more than ever, the eyes of the world are on sponsors to collaborate, sharing their clinical trial data to combat human health emergencies.

While individual patient-level data sharing is largely done on a voluntary basis, privacy is just as important as when clinical studies are published by regulators.

This webinar, held in collaboration with DIA, will investigate the different decisions pharma companies face and look at how these decisions impact brand reputation and public trust.

Featured Topics:

  • Data sharing as a clinical trial sponsor’s social responsibility
  • The real-world cost of not sharing safe, insight-rich data
  • A framework for safely sharing and using sensitive clinical trial data

Learning Objectives:

  • Compare qualitative and quantitative approaches to anonymization
  • Evaluate whether to build an in-house anonymization capability, buy software, or engage a vendor
  • Analyze methods for balancing patient privacy and data utility

Presenters

Niamh McGuinness, BPharm, PHD, Senior Analyst, Clinical Trial Transparency, Privacy Analytics
Laura Dodd, Global Data Sharing Manager, PRA Health Sciences, Takeda
Jingyi Liu, Principal Research Scientist, Eli Lilly and Company

Presenter

Niamh McGuinness is a technical lead with Privacy Analytics’ Clinical Trial Transparency (CTT) business unit. Her team works with a variety of clinical trial sponsors that have turned to us to meet the stringent requirements of regulations such as EMA Policy 0070 and Health Canada Public Release of Clinical Information (PRCI). Drawing on her academic research background, Niamh has helped develop Privacy Analytics’ CTT methodology and our proprietary toolsets.

Niamh McGuinness

Senior CTT Analyst

Read Full Bio

Join the next 5 Safes Data Privacy webinar

This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.

Register Now